secwatch.observer — SEC 8-K summary
======================================

Issuer:     NovoCure Ltd (NVCR)
CIK:        0001645113
Form:       8-K
Filed at:   2025-07-24T23:59:59+00:00
Accession:  0001645113-25-000030
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

NovoCure Q2 2025 revenue $158.8M (+6% YoY), net loss $40.1M; plans pancreatic cancer PMA in Q3
--------------------------------------------------------------------------------

- Net revenues $158.8M, up 6% YoY; net loss $40.1M ($0.36 loss per share); adjusted EBITDA -$9.9M.
- 4,331 active patients on TTFields globally; Optune Gio active patients up 7% YoY.
- Phase 3 PANOVA-3 pancreatic cancer trial met primary endpoint; PMA submission to FDA planned Q3 2025.
- PMA for brain metastases from NSCLC planned H2 2025; TRIDENT and PANOVA-4 readouts expected H1 2026.
- Cash and investments $911.5M as of June 30, 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000030/0001645113-25-000030-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1645113/000164511325000030/nvcr-20250724.htm
  HTML page:      https://secwatch.observer/filing/0001645113-25-000030

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer